Remission induction in childhood leukemia with second course vincristine (NSC-67574) and prednisone (NSC-10023) therapy.
D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004338:Drug Combinations; D005069:Evaluation Studies as Topic; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014750:Vincristine / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D004338:Drug Combinations; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate